$2.61
-0.09-3.33%
Last update: Oct 16, 6:26 PM
$2.58
-0.12-4.4%
Protalix BioTherapeutics Inc
PLXAMEX
Protalix BioTherapeutics (PLX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Protalix BioTherapeutics (PLX) last issued guidance on August 12, 2026 for fiscal year 2026. The company guided revenue in the range of $78M - $83M for the period.
Compared to prior guidance, Protalix BioTherapeutics maintained its revenue forecast from a prior range of $78M - $83M.
Protalix BioTherapeutics has issued 3 guidance updates between March 18, 2026 and August 12, 2026. This history provides investors with insight into management's expectations over time.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.01 | $-0.01 | $0.01 | $0.05 |
| Actual | $0.05 | $0.22 | $-0.06 | $0.03 |
| Surprise | +600.0% | +2300.0% | -700.0% | -40.0% |
| Revenue | ||||
| Estimate | $12.9M | $11.5M | $14.4M | $17.9M |
| Actual | $19.9M | $33.8M | $9.3M | $17.7M |
| Surprise | +53.8% | +194.3% | -35.2% | -1.09% |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $0.05 | $-0.01 | 600.0 % |
| Q1 | May 13, 2026 | $0.22 | $-0.01 | 2300.0 % |
| Q4 | Mar 18, 2026 | $-0.06 | $0.01 | -700.0 % |
| Q3 | Nov 13, 2025 | $0.03 | $0.05 | -40.0 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $19.90M | $12.94M | 53.8 % |
| Q1 | May 13, 2026 | $33.75M | $11.47M | 194.3 % |
| Q4 | Mar 18, 2026 | $9.30M | $14.36M | -35.2 % |
| Q3 | Nov 13, 2025 | $17.67M | $17.87M | -1.09 % |
